Sign inJoin waitlistJoin the waitlist

Brian Belyea

Associate Professor · University of Virginia Medical Center

Credentials: · · ·

History

University of Virginia Medical Center
Present
University of Virginia Medical Center
Present

Pediatric Hematology Oncology
Duke University Hospital
2008–2011
Pediatrics
University of Virginia Medical Center
2005–2008
University of Virginia School of Medicine
2000–2004
James Madison University
1996–2000

Research

Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls
Frontiers in Oncology · 2013 · 160 citations
FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma
Clinical Cancer Research · 2012 · 75 citations
A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma
Molecular Cancer Research · 2017 · 61 citations

RG
Roberto Gomez
9 papers
Corinne Linardic
6 papers
Ashley Hinson
2 papers · 2 as a resident
Rex Bentley
2 papers
AR
Abdelrahman Rahmy
1 paper
Abigail Kumral
1 paper · 1 as a resident
Agnes Fogo
1 paper
CM
Cassandra Moran
1 paper
CH
Christopher Heitz
1 paper · 1 as a fellow
Christopher Moskaluk
1 paper
Crystal Mackall
1 paper
David Kirsch
1 paper

Grants

Role of Renin Progenitors in Hematopoiesis
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $783.4K · University of Virginia
2014–2019

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Quality of End-of-Life Care for Children With Cancer
Site PI · Recruiting
Children's Oncology Group
2026–2031
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028